Literature DB >> 8280796

Infection of human cells with murine amphotropic replication-competent retroviruses.

K Cornetta1, N Nguyen, R A Morgan, D D Muenchau, J W Hartley, R M Blaese, W F Anderson.   

Abstract

Replication of the murine wild-type 4070A amphotropic retrovirus and a recombinant amphotropic replication-competent retrovirus arising from the PA12 packaging cell line varied considerably among the primate cell types tested. Medium from infected primate fibroblasts and endothelial cells contained the highest viral titers [10(4)-10(5) focus-forming units (ffu)/ml], while most hematopoietic cell lines, such as K562 and MOLT4, were associated with viral titers in the range of 10(3)-10(4) ffu/ml. Interestingly, HTLV-1-transformed T cell lines (TJF-2 and HM) and primary tumor infiltrating lymphocytes (TIL) had very low viral titer (0-10(1) ffu/ml). The low production of virus was not due to low infectivity and, in contrast to the virus, retroviral vectors were expressed without difficulty. Because screening for replication-competent retrovirus (RCR) is an important component of human retroviral-mediated gene therapy clinical protocols, a variety of assays were tested for their ability to detect RCR in virus-exposed cell lines. A biologic assay (3T3 amplification) and polymerase chain reaction (PCR) for the 4070A viral envelope are effective screening methods for RCR, even in cell lines associated with low virus production.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280796     DOI: 10.1089/hum.1993.4.5-579

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

1.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

2.  Gene Transfer to HSCs: Finding the Leukemia in Murine Leukemia Viruses.

Authors:  Kenneth Cornetta
Journal:  Mol Ther       Date:  2019-05-17       Impact factor: 11.454

3.  Adeno-associated virus type 2-mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells.

Authors:  K Qing; T Bachelot; P Mukherjee; X S Wang; L Peng; M C Yoder; P Leboulch; A Srivastava
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 4.  The National Gene Vector Biorepository: Eleven Years of Providing Resources to the Gene Therapy Community.

Authors:  Kenneth Cornetta; Lorraine Matheson; Ryan Long; Lisa Duffy
Journal:  Hum Gene Ther       Date:  2020-01-30       Impact factor: 5.695

5.  The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses.

Authors:  R K Naviaux; E Costanzi; M Haas; I M Verma
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Replication of enhancer-deficient amphotropic murine leukemia virus in human cells.

Authors:  F U Reuss; B Berdel; M Ploss; R Heber
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

7.  MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.

Authors:  Amy H Lin; Nina Timberlake; Christopher R Logg; Yanzheng Liu; Shuichi Kamijima; Oscar Diago; Kenneth Wong; Dawn K Gammon; Derek Ostertag; Katrin Hacke; Emily C Yang; Harry Gruber; Noriyuki Kasahara; Douglas J Jolly
Journal:  Hum Gene Ther       Date:  2014-06-18       Impact factor: 5.695

8.  A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay.

Authors:  A L Aloia; L Duffy; V Pak; K E Lee; S Sanchez-Martinez; D Derse; G Heidecker; K Cornetta; A Rein
Journal:  Gene Ther       Date:  2012-03-08       Impact factor: 5.250

9.  Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Authors:  Kenneth Cornetta; Lisa Duffy; Steven A Feldman; Crystal L Mackall; Marco L Davila; Kevin J Curran; Richard P Junghans; Jean Yuh Tang; James N Kochenderfer; Roisin O'Cearbhaill; Gary Archer; Hans-Peter Kiem; Nirali N Shah; Cindy Delbrook; Rosie Kaplan; Renier J Brentjens; Isabelle Rivière; Michel Sadelain; Steven A Rosenberg
Journal:  Mol Ther Methods Clin Dev       Date:  2018-08-17       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.